In the last years, the molecular profiling of these nanovesicles in the plasma of patients with NSCLC, offered the opportunity to delineate better the characteristics of the disease. Exosomes released from NSCLC patients contain proteins related to tumor growth and progression, such as EGFR, claudins, K-ras and inducers of matrix metalloproteinase synthesis like EMMPRIN [8] . Similarly to these findings, in other cancer types several exosomal proteins have been described with diagnostic and prognostic features, such as MIA and S100B in melanoma and Glypican-1 in early pancreatic cancer [9, 10] . So, these features might be exploited as a source of specific biomarkers because they reflect the pathological features of the disorder. Jakobsen et al. demonstrated the potential diagnostic properties of exosomal proteins in advanced NSCLC. Exosomes isolated from plasma of 109 NSCLC patients (stage IIIa − IV) and 110 healthy controls were analyzed with an extracellular vesicle array that phenotyped the exosomes directly from the plasma samples using 37 antibodies against lung cancer-related proteins, initiating the way to generate minimally invasive tools to detect exosome-derived biomarkers [11] . In this context, plasma from 431 lung cancer patients were analyzed in order to identify potential diagnosis proteins and demonstrating a protein profile associated to adenocarcinoma [12] . Other exosome's features suitable to be biomarkers have been also demonstrated in studies of other body fluids, such as urine. For example, Li et al., in NSCLC patients demonstrated a positive correlation rate of 65% between the presence of leucine-rich ␣-2-glycoprotein (LRG1) measured in primary tumor and in urinary exosomes. This study indicates that LRG1 in urinary exosomes might be derived from primary tumor tissue and, then, could be suitable as a non-invasive diagnostic biomarker of NSCLC in this selected population [13] . In preclinical analysis with NSCLC cell lines, a proteomic profiling was performed in exosomes identifying a total of 721 proteins. Among these, several proteins such as EGFR, SRC and GRB2, were found really enriched, suggesting then their potential prognostic biomarker role in NSCLC patients [14] . Recently, it has been described for the first time the translocation ALK-EML4 inside exosomes from NSCLC patients, broadening exosome characterization as a powerful tool for molecular identification [15] .
Exosomes have been described also as delivery systems, specifically, exosomes derived from dendritic cells (DEX) have been studied as possible immunotherapy components since they carry major histocompatibility complex (MHC) molecules and are able to present antigens to immune cells as CD4 and CD8T lymphocytes [16] . A phase I and a phase II trial have been performed with DEX, concluding in both cases the safety of the administration of DEX and DEX carrying IL-15Ra and NKG2D and the ability of DEX to activate both innate and adaptive immune systems [17, 18] .
In addition to their effects on the primary tumor microenvironment, exosomes also play a strong role, together with chemokines, in the establishment of the pre-metastatic niche. In SCID mice it has been demonstrated that there is a lung pre-metastatic niche formation mediated also by CD105-positive exosomes through an upregulation of proteins such as VEGFR1, MMP2 and MMP9 [19] . In other preclinical studies, exosomes were also described as potential drug resistance vectors. Xiao et al. demonstrated in vitro that exosomes released by A549 cells were involved in the regulation of the sensitivity of these cells to DNA-damaging Platinum (DDP) Furthermore, exosomes released by A549 cells during DDP exposure decreased the sensitivity of other untreated A549 cells to DDP, which may be mediated by exosome-mediated proteins, miRNAs and mRNAs cell exchange [20] .
The characterization of tissular miRNA profiles in NSCLC patient's [21, 22] prompts the idea that exosomal miRNA profile could also mirror the tumoral tissue profile, and serve as a specific liquid biopsy biomarker [23] . In this regards, Rabinowits et al., for the first time, demonstrated that in lung adenocarcinoma patients there is a similarity between exosomal miRNAs and tumor-derived miRNAs profiles, suggesting that 12 specific exosomal miRNAs (miR-17-3p, miR-21, miR-106a, miR-146, miR-155, miR-191 , miR-192, miR-203, miR-205, miR-210, miR-212, and miR-214) might be useful as screening biomarkers for lung adenocarcinoma [24] . Recent studies have also been performed in order to understand the role of miRNAs in exosomes released in other body fluids. Rodriguez et al. performed a prospective exosomal analysis in blood and bronchoalveolar lavage (BAL) samples from 30 NSCLC patients and 75 controls [25] . The results showed that increased amounts of exosomes were detected in plasma compared than in BAL samples in both groups. Additionally, miR-302-a and miR-302-c were detected specifically in BAL and miR-126 in plasma, suggesting a selective tumor-derived exosome destination and a selected exosomal disposal of miRNAs in NSCLC patients.
Exosomes are important components of the liquid biopsy, that contain proteins and nucleic acids that permit to get a specific tumor molecular profile, and may act as a surrogate tumor-ID-card. This could help in establishing non-invasive diagnostic, prognostic and drug resistance biomarkers that could be crucial for managing NSCLC patients. Additional studies are mandatory in order to translate these discoveries to the clinical setting, especially in the standardization of the exosome isolation and characterization methods, which they are still debated.
